This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Patient Safety/ Medical Error  • Renal Diseases, Other  • Surgery  • Colorectal Surgery  • Gastrointestinal Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Kevin C. Abbott, MD, MPH; Erin M. Bohen, MD; Frank P. Hurst, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Oral phosphosoda (OSP) is currently the dominant bowel purgative in the United States. However, recent appreciation of the syndrome of acute phosphate nephropathy and its possible association with the use of OSP have raised potential concerns about the risk-benefit balance of OSP use for bowel preparation. The recent article by Khurana et al¹ adds important information to this controversy because it is one of the few population-based studies in which OSP use has been associated with a statistically significant alteration in kidney function. Because the accompanying editorial called for larger studies that included polyethylene glycol (PEG) control groups,² we would like to call attention to 3 recently published studies that fulfill those criteria. Furthermore, as authors of one of those studies, we would like to share additional findings that were not reported in our original study that . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?